Urology Cancer Center PC
Welcome,         Profile    Billing    Logout  
 57 Trials 
107 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Johnson, Jennifer E
NCT06541951: Scaling up Maternal Health Equity Best Practices

Not yet recruiting
4
600
US
Services as usual, Scale-up implementation approach
Michigan State University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Maternal Mortality Disparities, Maternal Morbidity Disparities
04/30
11/30
DREAM, NCT05069428: Delirium Reduction With Ramelteon

Recruiting
4
506
US
Ramelteon 8mg
Centennial Medical Center
Delirium
03/25
12/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT03811015: Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Suspended
3
636
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
01/27
01/27
ROSES-II, NCT05700760: The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention

Recruiting
3
2320
US
ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns), Enhanced Care as Usual (CAU)
Michigan State University, Pacific Institute for Research and Evaluation, Henry Ford Health System, Butler Hospital
Postpartum Depression
12/27
12/27
HeAL, NCT04629599: IPT for Major Depression Following Perinatal Loss: Healing After Loss

Recruiting
2/3
274
US
Interpersonal psychotherapy for major depression following perinatal loss, IPT, Coping with Depression, CWD
Michigan State University, Women and Infants Hospital of Rhode Island
Major Depressive Disorder
11/25
11/25
RTOG 1216, NCT01810913: Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Recruiting
2/3
613
Canada, US, RoW
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cetuximab, C 225, C-225, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), NRG Oncology
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
01/27
01/27
ECOG-ACRIN EA3202, NCT05063552: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Recruiting
2/3
430
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cetuximab, C 225, C-225, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
12/27
12/27
NCT03076281: Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

Active, not recruiting
2
7
US
Metformin Hydrochloride, 1,1-Dimethylbiguanide Hydrochloride, 1115-70-4, 91485, Cidophage, Dimefor, Glucoformin, Glucophage, Glifage, Doxycycline, 17086-28-1, Doxycycline Monohydrate, Metformin +Doxycycline
Sidney Kimmel Cancer Center at Thomas Jefferson University
Larynx, LIP, Oral Cavity, Pharynx
12/18
08/20
NCT02874430: Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

Active, not recruiting
2
27
US
Metformin Hydrochloride, 1,1-Dimethylbiguanide Hydrochloride, 1115-70-4, 91485, Cidophage, Dimefor, Glifage, Glucoformin, Glucophage, N,N-Dimethylimidodicarbonimidic Diamide Monohydrochloride, Riomet, Siofor, Doxycycline, 17086-28-1, Doxycycline Monohydrate
Sidney Kimmel Cancer Center at Thomas Jefferson University
Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma
12/20
06/23
immunoMATCH, NCT05136196: BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an Pilot Study

Suspended
2
150
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Melanoma
01/27
01/27
NCT04671667: Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recruiting
2
188
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Proton Beam Radiation Therapy, External beam radiation therapy protons (procedure), External Beam Radiotherapy (protons), PBRT, Proton, Proton EBRT, Proton External Beam Radiotherapy, Proton Radiation Therapy, PROTON Therapy, Radiation, Proton Beam
National Cancer Institute (NCI)
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
02/26
02/26
NCT05564377: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Recruiting
2
2900
US
Alpelisib, BYL 719, BYL-719, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Binimetinib, ARRY 162, ARRY 438162, ARRY-162, ARRY-438162, ARRY162, ARRY438162, MEK 162, MEK-162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ICI-182780, ICI182780, ZD 9238, ZD-9238, ZD9238, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mutation Carrier Screening, Neratinib Maleate, 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1), HKI-272 Maleate, NERATINIB MALEATE ANHYDROUS, Nerlynx, Nilotinib Hydrochloride Monohydrate, AMN 107, AMN-107, AMN107, Nilotinib Monohydrochloride Monohydrate, Tasigna, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, Elplat, JM 83, JM-83, JM83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, RP54780, SR 96669, SR-96669, SR96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate, Sotorasib, AMG 510, AMG-510, AMG510, Lumakras, Lumykras
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
07/30
07/30
NCT04442126 / 2021-000441-41: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Terminated
1/2
52
Europe, US, RoW
NM21-1480
Numab Therapeutics AG
Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
02/24
02/24
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
NCT04713657: Beta-blocker Administration for Cardiomyocyte Division

Recruiting
1
40
US
N-thymidine, Thymidine, Urine Collection, Echocardiogram, Cardiac MRI, Propranolol Hydrochloride, Propranolol, Placebo, Physical Exam, Specimen Collection
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI)
Tetralogy of Fallot, Double Outlet Right Ventricle
12/30
12/30
KEYNOTE-D44, NCT04609579: Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Terminated
1
27
US
SNX281, pembrolizumab, KEYTRUDA®
Stingthera, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Lymphoma
01/24
01/24
ROSE, NCT03267563: Minimum Intervention to Maintain a Postpartum Depression Prevention Program in Clinics Serving Low-income Women

Active, not recruiting
N/A
800
US
EIAU, LICF, HICF
Michigan State University, Butler Hospital, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), Palo Alto Veterans Institute for Research, University of Rochester, University of Massachusetts, Worcester, Pacific Institute for Research and Evaluation
Depression, Postpartum
10/23
12/23
NCT06573749: Effect of 12-week Milk Fat Globule Membrane Supplementation on the Human Muscle Function of Middle-aged Exercisers

Not yet recruiting
N/A
48
Europe
Bioactive whey protein concentrate, Pea-based protein supplement
Loughborough University, Volac International Limited
Ageing Well, Age-Related Atrophy, Age-Related Sarcopenia
07/25
07/25
MIRACLE, NCT05386316: The Maternal Health Multilevel Intervention for Racial Equity () Project

Enrolling by invitation
N/A
540000
US
Multilevel intervention for racial disparities in severe maternal morbidity and mortality, Standard Enhanced Prenatal Care (EPC) services
Michigan State University, Spectrum Health Hospitals, Hurley MIHP and Healthy Start, Ascension MIHP and Healthy Start, Genesee County Health Department, Community Based Organization Partners
Maternal Morbidity and Mortality, Health Disparities
12/25
12/25
ROOT, NCT04028479: The Registry of Oncology Outcomes Associated with Testing and Treatment

Completed
N/A
167
US
Biomarker Testing (L), Biomarker Testing, Molecular Testing, Next-generation sequencing (NGS), Multiplex molecular testing, Systemic Treatment (T), Biologic therapy, Targeted therapy, Immunotherapy, Chemotherapy, Patient Reported Outcomes (P), Patient experience, Quality of life, Self-reporting
Taproot Health
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
10/24
10/24
Kim, Hyun Soo
COALA, NCT05383183: Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease

Recruiting
4
630
RoW
Choline Alfoscerate 400mg, Placebo
Daewoong Bio Inc.
Alzheimer Disease
06/25
12/25
NCT05803941: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Recruiting
4
700
Europe, Canada, US, RoW
AAA617, lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617
Novartis Pharmaceuticals
Prostate Cancer
07/33
07/33
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
PROUD, NCT05666804: Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Recruiting
3
160
RoW
Brolucizumab 6mg, Beovu
Novartis Pharmaceuticals
Macular Polypoidal Choroidal Vasculopathy (PCV)
09/25
09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
PRECISIONS, NCT04300920: Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection () Trial

Active, not recruiting
3
202
US
N-acetyl cysteine, NAC, Placebo
Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation
Idiopathic Pulmonary Fibrosis
02/26
02/26
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
NCT03132974: Evaluation of Efficacy and Safety of Single and Multiple Therapy of Herbal Medicine/Chuna Therapy on Non-specific Chronic Low Back Pain: A Study Protocol for Multicenter, 3-arm, Randomized, Single Blinded, Parallel Group, Incomplete Factorial Design, Pilot Study -

Recruiting
2/3
150
RoW
Sogyeonghwalhyeol-tang granule, Sogyeonghwalhyeol-tang granule with manipulation procedure, Placebo with manipulation procedure
Gachon University Gil Oriental Medical Hospital, Daejeon University, Semyung University Korean Medicine Hospital in Chungju, Woosuk University Oriental Medical Center
Chronic Low Back Pain
12/21
12/21
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
NCT04541173: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Terminated
2
6
US
Y-90 TARE, Atezolizumab, Tecentriq, Bevacizumab, Avastin
Aiwu Ruth He, MD, Georgetown University, Genentech, Inc.
Hepatocellular Carcinoma
06/23
06/23
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24
NCT04162665: Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Terminated
2
4
US
Adaptive short course radiation therapy, Standard of care chemotherapy regimen
Washington University School of Medicine, Viewray Inc.
Gastric Adenocarcinoma
12/23
11/24
NCT04331041: Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

Recruiting
2
42
US
Adaptive stereotactic body radiation therapy, Adaptive SBRT, Defactinib, VS-6063, PF-04554878, Tumor biopsy, Research blood draw
Washington University School of Medicine, National Cancer Institute (NCI), Verastem, Inc.
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
06/27
06/28
NCT04166318: Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Recruiting
2
252
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Mitomycin, Ametycine, MITO, MITO-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
12/29
12/29
NCT02899091: Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease

Active, not recruiting
1/2
24
RoW
CB-AC-02, Placebo
CHABiotech CO., Ltd
Alzheimer's Disease
12/24
12/24
NCT05877430: Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Recruiting
1/2
160
US, RoW
CJRB-101, Pembrolizumab injection
CJ Bioscience, Inc.
NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
07/26
10/27
BET-PSMA-121, NCT05413850: Anti-tumour Activity of (177Lu) RhPSMA-10.1 Injection

Recruiting
1/2
150
Europe, US
177Lu-rhPSMA-10.1 injection, 177Lu-rhPSMA-10.1, 18F-rhPSMA-7.3 injection, 18F-rhPSMA-7.3
Blue Earth Therapeutics Ltd, PSI CRO
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, MCRPC, Urogenital Neoplasms, Prostatic Neoplasms, Prostatic Diseases
08/26
10/26
NCT03516708: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Hourglass Jan 2019 - Jan 2019 : P1/2 trial in advanced rectal cancer
Recruiting
1/2
49
US
Epacadostat, INCB024360, Short-course radiation therapy, SCRT, CAPOX chemotherapy, FOLFOX chemotherapy
Washington University School of Medicine, Incyte Corporation, National Cancer Institute (NCI)
Rectal Cancer
07/27
08/30
NCT05039905: SLN Detection With Tc-MSA-ICG in Lung Cancer Patients

Recruiting
1
10
RoW
99mTc-MSA-ICG
Korea University Guro Hospital
Lung Cancer
12/21
12/21
NCT04046575: Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer

Recruiting
1
20
US
Intensity Modulated Radiation Therapy, IMRT, Carboplatin, Paraplatin, MD Anderson Symptom Inventory (MDASI)-Plus module, EuroQol (EQ-5D), SF-12, MOS Social Support Measure, CES-D, Blood for ctDNA (optional), Blood for SCCA, Paclitaxel, Taxol
Washington University School of Medicine
Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
09/25
09/27
NCT06167941: Identification of Integrin ab Expression in Lung Cancer Patients

Completed
N/A
61
RoW
Lung cancer types
Korea University Guro Hospital
Expression of Integrin ανβ3 in Lung Cancer
09/21
11/21
NCT04441970: The Influence of Head and Neck Position on the Cuff Pressure Using Nasotracheal Tube

Recruiting
N/A
50
RoW
Neutral position, Head extension position, Head flexion position, Head rotation position
Yonsei University
Adult Patients Over 20 Years of Age Who Require Intubation of the Nasotracheal Tube to Undergo Oral and Maxillofacial Surgery Under General Anesthesia
12/20
03/21
NCT04499222: Assessment of Tube Position According to the Changes of Neck Position Between Two Different Types of Nasotracheal Tubes

Not yet recruiting
N/A
40
RoW
Portex, Mallinckrodt
Yonsei University
Nasotracheal Intubation
05/22
05/25
NCT03415919: Collection of Gastrointestinal Malignant and Non-malignant Human Samples

Enrolling by invitation
N/A
300
US
no intervention will be given to patients.
University of Texas at Austin
Inflammatory Bowel Diseases, Colo-rectal Cancer
07/22
07/22
NCT03962374: The Comparison of the Success Rate of the Endotracheal Intubation Between the Stylet and the Frova With Acute Angled Videolaryngoscope

Recruiting
N/A
166
RoW
Frova, Stylet
Yonsei University
Anesthesia, General
05/23
06/23
NCT05255588: A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer

Recruiting
N/A
2358
RoW
EarlyTect® CRC test
Genomictree, Inc., Soon Chun Hyang University, Gangnam Severance Hospital, Kyung Hee University Hospital at Gangdong, Kangbuk Samsung Hospital, Kyung Hee University Hospital, Keimyung University Dongsan Medical Center, Korea University Anam Hospital, Pusan National University Hospital, The Catholic Univ. of Korea Bucheon ST. Mary's Hospital, Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, Wonju Severance Christian Hospital, Severance Hospital
Colorectal Cancer, Advanced Colorectal Neoplasm, Advanced Adenomas, Non-neoplastic Polyps, Non-advanced Adenomas
02/24
02/24
NCT05571982: Comparison of the Efficacy of Tidal Volume Breathing and Vital Capacity Breathing During High-flow Nasal Oxygen

Not yet recruiting
N/A
58
RoW
Tidal volume breathing technique, Vital capacity breathing technique
Yonsei University
Adult Patients 20 Years of Age or Older Who Are Planning to Undergo Surgery Under General Anesthesia
09/23
09/24
ASSURE, NCT03306901: Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma

Active, not recruiting
N/A
240
RoW
Esophagectomy, 5-fluorouracil, 5-FU, Cisplatin, Radiation therapy
Samsung Medical Center, Ministry of Health & Welfare, Korea
Esophageal Cancer
12/25
12/33
NCT06583434: Effects of Stabilization-based Pilates Exercise on Gait and Balance in Women With Flexible Pesplanus

Completed
N/A
22
RoW
core-lower extremity Pilates Training Group, Non-Training Group
Hyun Ju Kim
Flexible Flatfoot
03/24
03/24
NCT05987007: Sleep Interventions and Neurocognitive Outcomes

Not yet recruiting
N/A
50
US
Acoustic slow-wave activity enhancement, Cognitive behavioral therapy for insomnia
New York State Psychiatric Institute, Columbia University
Sleep Disturbance, Amnestic Mild Cognitive Impairment
12/27
12/27
NCT05471401: GI Organ Tracking Via Balloon Applicators

Withdrawn
N/A
10
NA
Balloon-tipped catheter
Washington University School of Medicine
Esophageal Cancer, Kidney Cancer, Larynx Cancer, Liver Cancer, Lung Cancer, Digestive Organs--Cancer, Intrathoracic--Cancer, Respiratory Organs--Cancer, Pancreas Cancer, Small Intestine Cancer, Stomach Cancer, Colon Cancer, Rectal Cancer
04/25
05/25
Dragon, NCT05427214: Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

Completed
N/A
52
US
Halcyon 4.0 system
Washington University School of Medicine, Varian Medical Systems
Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastric Cancer, Ovarian Cancer, Colon Cancer
10/24
10/24
PARTy, NCT06310655: Online Proton Adaptive Radiotherapy

Recruiting
N/A
10
US
Proton SBRT
Washington University School of Medicine, The Foundation for Barnes-Jewish Hospital
Solid Tumor
05/25
08/25
NCT06497283: Binaural Sound for Remimazolam Maintenance

Recruiting
N/A
72
RoW
Binaural sound
Gangnam Severance Hospital
General Anesthesia, Prostate Cancer Stage, Uterine Myoma
02/25
02/25
NCT06705946: Effects of Water Inertia Load Training on Lower Limb Joint Moments, Gait, and Balance in Elderly Women

Enrolling by invitation
N/A
30
RoW
Aqua vest group, Weight vest group
Hyun Ju Kim
Balance and Gait Impairment in Elderly Women
02/25
02/25
IMPARC, NCT04827732: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer

Recruiting
N/A
23
US
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy, IMPT, MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
Washington University School of Medicine
Recurrent Rectal Cancer
12/25
01/26
KOBIO, NCT01965132: Korean College of Rheumatology Biologics and Targeted Therapy Registry

Recruiting
N/A
10000
RoW
Biologic or targeted synthetic DMARD, etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab, ixekizumab, or biosimilars, tofacitinib, baricitinib, upadacitinib
Seoul National University Hospital
Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
12/29
06/30
NOM-ERA, NCT03904043: Non-Operative Management and Early Response Assessment in Rectal Cancer

Active, not recruiting
N/A
63
US
Radiation therapy, FOLFOX regimen, Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire, Rectal biopsy samples, Blood for ctDNA
Washington University School of Medicine
Adenocarcinoma of the Lower Rectum
08/24
04/26
TTM-COHB, NCT04975867: Adjunct Targeted Temperature Management in Acute Severe Carbon Monoxide Poisoning

Recruiting
N/A
46
RoW
Targeted therapeutic hypothermia, Targeted therapeutic normothermia
Wonju Severance Christian Hospital, National Research Foundation of Korea
Carbon Monoxide Poisoning, Neurologic Sequelae, Hypothermia
12/24
07/25
ARTIA-Pancreas, NCT05764720: Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

Recruiting
N/A
134
US
Daily Adaptive External Beam Radiation Therapy
Varian, a Siemens Healthineers Company, Washington University School of Medicine
Pancreatic Cancer
02/26
02/28
NCT05369182: Multicenter Registry of Coronary Flow-Derived Indexes for Coronary Microvascular Disease (Multicenter FLOW-CMD Registry)

Active, not recruiting
N/A
1000
RoW
Invasive physiologic assessment, Intravascular imaging
Samsung Medical Center, Chonnam National University Hospital, Chosun University Hospital, Seoul National University Bundang Hospital, Seoul St. Mary's Hospital
Coronary Microvascular Disease, Coronary Artery Disease, Ischemic Heart Disease
11/26
12/27
METEOR-CRATR, NCT05975593: MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

Recruiting
N/A
60
US
Tumor collection via biopsy, Blood collection, Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI), DBSI MRI
Washington University School of Medicine, National Cancer Institute (NCI)
Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Cancer, Cervical Cancer, Pancreas Cancer, Pancreatic Cancer, Cancer of the Cervix, Cancer of the Pancreas
12/32
12/32
NCT05587114: Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood

Recruiting
N/A
150
RoW
frozen blood plasma samples
Korea University Guro Hospital
Lung Cancer, Diagnosis
12/24
12/25
Nordquist, Luke
NCT05803941: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Recruiting
4
700
Europe, Canada, US, RoW
AAA617, lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617
Novartis Pharmaceuticals
Prostate Cancer
07/33
07/33
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
CURLu177PSM0001, NCT05204927: 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
439
Europe, US
177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide
Curium US LLC
Metastasis From Malignant Tumor of Prostate
08/24
02/29
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
02/25
02/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
DORA, NCT03574571 / 2018-002944-10: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
AlphaBreak, NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hourglass May 2024 - Dec 2024 : Completion of enrollment in P2 portion for mCRPC
Recruiting
2/3
60
US
FPI-2265, Ac225-PSMA I&T
Fusion Pharmaceuticals Inc.
Metastatic Castration-resistant Prostate Cancer
07/26
01/31
NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Completed
2
61
US
GT0918, proxalutamide, androgen receptor antagonist
Suzhou Kintor Pharmaceutical Inc,
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
03/22
09/22
SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer

Completed
2
53
US
64Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
05/24
05/24
TATCIST, NCT05219500: Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer ().

Recruiting
2
115
US
FPI-2265, Ac225-PSMA I&T
Fusion Pharmaceuticals Inc.
Metastatic Castration Resistant Prostate Cancer
12/24
12/25
CONVERGE-01, NCT06549465: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer

Recruiting
2
47
US
In-111 rosopatamab tetraxetan, 45 KBq/kg Ac-225 rosopatamab tetraxetan, 55 KBq/kg Ac-225 rosopatamab tetraxetan, 60 KBq/kg Ac-225 rosopatamab tetraxetan
Convergent Therapeutics
PSMA PET-Positive Castration-Resistant Prostate Cancer
12/25
04/27
NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial)

Active, not recruiting
2
234
US
Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide
Dana-Farber Cancer Institute, Bayer, Decipher Biosciences
Prostate Cancer
03/25
03/28
PSMACare, NCT05849298: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Recruiting
2
120
Europe, Canada, US, RoW
AAA617, Lutetium [177Lu] vipivotide tetraxetan, 177Lu-PSMA-617, AAA517, 68Ga-PSMA-11, Piflufolastat F 18, ARPI, ADT, Best supportive care
Novartis Pharmaceuticals
Prostatic Neoplasm
10/27
12/28
HEAT, NCT06014255: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Recruiting
2
219
US
Enoblituzumab, MGA271, Standard of Care
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics
Prostate Cancer
03/29
03/29
NCT05286840: 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

Not yet recruiting
1/2
150
US
64Cu-SAR-bisPSMA
Luke Nordquist, MD, Clarity Pharmaceuticals
Prostate Cancer
03/23
09/23
COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer

Completed
1/2
52
US
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
08/23
08/23
COMBAT, NCT05633160: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617

Recruiting
1/2
38
US
64Cu-SAR-BBN, 67Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Prostatic Neoplasms, Castration-Resistant
05/26
05/26
PRESERVE-006, NCT05682443: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Recruiting
1/2
144
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto
OncoC4, Inc., Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer
06/26
06/27
NCT05617040: Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Active, not recruiting
1/2
144
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
08/26
04/27
SECURE, NCT04868604: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Recruiting
1/2
44
US
64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostatic Neoplasms, Castration-Resistant
09/26
09/26
ONCT-534-101, NCT05917470: A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Terminated
1/2
21
Europe, US
ONCT-534, GTx-534, UT-34
Oncternal Therapeutics, Inc
Metastatic Castration-resistant Prostate Cancer
09/24
09/24
NCT05773703: Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Completed
1
23
US
PSMA-Targeted [In-111]-Labeled Trillium Compound, PTI-122
Ratio Therapeutics, Inc.
Prostate Cancer
12/23
12/23
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
NCT05283330: Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Recruiting
1
30
US
²¹²Pb-DOTAM-GRPR1
Orano Med LLC
Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
08/24
01/25
NCT05605522: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Active, not recruiting
1
42
US, RoW
[225]-FPI-2059, [111In]-FPI-2058
Fusion Pharmaceuticals Inc.
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
06/25
09/25
Baird, Kim
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
Frank, Laura
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
NCT03606174: A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Hourglass Jul 2022 - Dec 2022 : Interim data from trial in combination with Opdivo for 2L/3L bladder cancer
Hourglass Jan 2021 - Dec 2021 : Additional data from trial in combination with nivolumab for 2L/3L bladder cancer
Checkmark From trial in combination with Opdivo for urothelial cancer at ESMO 2020
Sep 2020 - Sep 2020: From trial in combination with Opdivo for urothelial cancer at ESMO 2020
Checkmark From trial in combination with Opdivo for urothelial cancer at SITC 2019
More
Terminated
2
260
US
Sitravatinib, MGCD516, Nivolumab, Opdivo, Pembrolizumab, Keytruda, Enfortumab vedotin, Padcev
Mirati Therapeutics Inc.
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
08/22
08/22
COMBAT, NCT05633160: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617

Recruiting
1/2
38
US
64Cu-SAR-BBN, 67Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Prostatic Neoplasms, Castration-Resistant
05/26
05/26
 

Download Options